TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05317676
Drug: Palmitoylethanolamide
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-month supply of PEA will be given upon discharge. 300mg will be taken twice a day in conjunction with discharge medications (opioid and NSAIDs).
Study: NCT06001151
Drug: Cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive cadonilimab (10mg/kg) every 3 weeks.
Study: NCT06001151
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients receive pemetrexed (500mg/m2) every 3 weeks.
Study: NCT06001151
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive carboplatin (AUC=5) every 3 weeks for 4 cycles.
Study: NCT06205641
Drug: Baloxavir Marboxil Tablet
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Take Baloxavir Marboxil Tablet 2 tablets orally, once a day, for 1 day.
Study: NCT05471440
Drug: Post-poned boost mRNA
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be boosted with a covid-19 vaccin after priming with mRNA
Study: NCT05471440
Drug: Post-poned boost adeno
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be boosted with a covid-19 vaccin after priming with adeno
Study: NCT00000770
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000770
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000770
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04752033
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose titration utilizing will be done using sequential up and down design using biased coin method. All participant will receive a morphine dose that is within the range of doses currently utilized clinically and no participant will receive placebo only.
Study: NCT04752033
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose titration utilizing will be done using sequential up and down design using biased coin method. All participant will receive a hydromorphone dose that is within the range of doses currently utilized clinically and no participant will receive placebo only.
Study: NCT06287086
Drug: BRL-101 autologous hematopoietic stem and progenitor cells injection
Normalized name: human cord blood hematopoietic progenitor cell
DrugBank: Human cord blood hematopoietic progenitor cell (DB11054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.
Study: NCT05005299
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax is administered as an oral tablet once daily.
Study: NCT05005299
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine is administered as an intravenous infusion at a dose of 30mg/m2 daily, to be administered over 30 minutes.
Study: NCT05611905
Drug: Probenecid
Normalized name: Probenecid
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dose of 500 mg (tablet) 2 hours before IV dose of 11C-PABA will be administered.
Study: NCT05585736
Drug: Cycloplegics
Normalized name: MYDRIATICS AND CYCLOPLEGICS
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: they are drugs that paralyze the ciliary muscles and cause relaxation of accommodation.
Study: NCT00002406
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05269537
Drug: Intrathecal Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
Study: NCT05269537
Drug: Intravenous Ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
Study: NCT05269537
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin 10 U in 500 mL Ringer acetate will be administered over 30 minutes starting immediately after delivery of the fetus
Study: NCT05167084
Drug: Metyrapone 250 mg Oral Tablets
Normalized name: metyrapone 250 MG
DrugBank: Metyrapone (DB01011)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-1, day 2 1-2-2, day 3 2-2-3 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-3-4 day 8 3-0-0
Study: NCT05355129
Drug: TT-00920
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT05435911
Drug: REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]
Normalized name: remimazolam besylate 2.5 mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [BYFAVO]
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam Besylate is used as an intervention drug for general anesthesia, followed by flumazenil administration at the end of anesthesia, compared to propofol-based total intravenous anesthesia during breast cancer surgery under general anesthesia
Study: NCT05435911
Drug: Flumazenil
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil is used as an additional intervention drug to facilitate emergence from general anesthesia in the Remimazolam with Flumazenil group.
Study: NCT05435911
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol is used as an active comparator drug for general anesthesia until the end of anesthesia, to be compared to remimazolam besylate during breast cancer surgery under general anesthesia.
Study: NCT06282640
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D replacement therapy was administered at 50,000 IU weekly for 8 weeks.
Study: NCT04814602
Drug: Proglumide
Normalized name: proglumide
DrugBank: Proglumide (DB13431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCK receptor antagonist
Study: NCT05068947
Drug: GV101
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GV101 administered once orally.
Study: NCT06378697
Drug: AK111
Normalized name: Alpelisib
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: AK111 subcutaneous injection at week 0,1, 4 and 4-weekly thereafter until week 48.
Study: NCT06097962
Drug: NK510
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion
Study: NCT06097962
Drug: Tislelizumab，atezolizumab or sugemalimab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administer according to the instructions
Study: NCT05921071
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One gram of tranexamic acid (Hexakapron) is administered intravenously before surgery
Study: NCT05509543
Drug: IY-NT-T
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 20mg
Study: NCT05572749
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin will be administered in a dosage of 1000mg per day. Metformin is a formally approved therapy for children with diabetes in Europe.
Study: NCT04996368
Drug: Tranexamic acid injection
Normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomized comparison of two doses of tranexamic acid as prophylactic before start of incision in open heart surgery use for prevention of bleeding.
Study: NCT04855110
Drug: Warfarin Sodium started on Day 2 after caesarean section (in a dose that achieves a therapeutic level as indicated by the cardiology consultant)
Normalized name: warfarin sodium 2 MG
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin started on day 2 after caesarean section in patients with mechanical heart valve prosthesis
Study: NCT04855110
Drug: Warfarin Sodium started on day 5 after caesarean section (in a dose that achieves a therapeutic level as indicated by the cardiology consultant)
Normalized name: warfarin sodium 5 MG
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin started on day 5 after caesarean section in patients with mechanical heart valve prosthesis
Study: NCT05721443
Drug: Dalpiciclib+cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The dosing regimen for cetuximab combined with dalpiciclib is: the starting dose of cetuximab is 400 mg/m2, titrated over 120 minutes, and the titration rate should be limited to 5 ml/min. A maintenance dose of 250 mg/m2, titrated over not less than 60 minutes, with pretreatment with H1 receptor blocker desensitization prior to dosing, administered once weekly.~The recommended dose of dalpiciclib is 150 mg once daily for 21 days, followed by 7 days of discontinuation (3/1 dosing regimen) for a 28-day treatment cycle. Take the drug at approximately the same time each day. If the patient vomits or misses a dose, the dose should not be made up that day. The next dose should be taken as usual.~Subjects will continue treatment with cetuximab in combination with dalpiciclib until termination criteria are met.
Study: NCT04814056
Drug: Afatinib Dimaleate
Normalized name: afatinib dimaleate
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib is the second-generation TKI drug, which can irreversibly bind to receptors of erbB family. Afatinib will be administered orally at a dose of 40 mg per time, Q.D. If a patient cannot tolerate a dose of 40mg due to adverse reactions, when the adverse reactions restore to level 1 (CTCAE 5.0) or below, the dosage could be adjusted to 30mg per day, Q.D.
Study: NCT00002430
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002430
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002430
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002430
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04847245
Drug: Pregabalin 75mg tid + Duloxetine
Normalized name: pregabalin 75 MG
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin capsules were administered orally (75 mg, 3 times a day), combined administration of duloxetine (60-120 mg/day）.
Study: NCT04847245
Drug: Intravenous administration of esketamine 0.125 mg/kg+Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous administration of esketamine 0.125 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
Study: NCT04847245
Drug: Intravenous administration of esketamine 0.25 mg/kg +Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous administration of esketamine 0.25 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
Study: NCT04847245
Drug: Intravenous administration of esketamine 0.50 mg/kg+Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous administration of esketamine 0.50 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
Study: NCT05492968
Drug: Epinephrin
Normalized name: Epinephrin
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the epinephrine group will receive a continuous infusion containing epinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
Study: NCT05492968
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the phenylephrine group will receive a continuous infusion containing phenylephrine with a concentration of 0.2mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
Study: NCT05140083
Drug: 68Ga-NOTA Evans Blue
Normalized name: Evans blue
DrugBank: Evans blue (DB09361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject receives a single subcutaneous injection of 68Ga-NOTA Evans Blue, and undergo PET/CT imaging within the specific time.
Study: NCT04974723
Drug: Abaloparatide
Normalized name: Abaloparatide
DrugBank: Abaloparatide (DB05084)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abaloparatide subcutaneous (abaloparatide SC \[ABL\]; Tymlos®)
Study: NCT04974723
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide subcutaneous (TPTD; Forteo®)
Study: NCT04696783
Drug: Esomeprazole Magnesium Enteric-coated Tablets
Normalized name: esomeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nexium taken once every 2 days plus lifestyle adjustment
Study: NCT05749861
Drug: CKD-348(5)
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT05082142
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the intervention arm will receive 1g of intraoperative IV TXA during the HoLEP procedure.
Study: NCT06360211
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration
Study: NCT06457100
Drug: Esmolol Injection
Normalized name: esmolol Injection
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Before induction of anesthesia, 0.5 mg/kg of esmolol was pumped intravenously and infused within 1 minute, followed by a pumping rate of 3 mg/kg/h until the end of the procedure.
Study: NCT06457100
Drug: Lidocaine IV
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Before induction of anesthesia, 2 mg/kg of lidocaine was pumped intravenously and infused within 10 minute, followed by a pumping rate of 2 mg/kg/h until the end of the procedure.
Study: NCT05578508
Drug: Mesenchymal Stem Cells (MSCs)
Normalized name: Autologous adipose derived mesenchymal stem cells (MSCS)
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection of allogeneic bone marrow derived mesenchymal stem cells (MSCs) to the ileal pouch.
Study: NCT06384378
Drug: 11C-ER176
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER176 is a PET tracer that binds to the 18 kDa translocator protein (TSPO), which is expressed by activated microglia and astrocytes and is therefore an index of brain inflammation.
Study: NCT06297681
Drug: Daratumumab + Bortezomib + Dexamethasone + Dapagliflozin
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The treatment medication for enrolled patients must comply with the treatment regimen of Daratumumab + Bortezomib + Dexamethasone: subcutaneous injection of 1800mg of Daratumumab, d1, 8,15,22 (28 day cycle); (After 2 cycles of improvement in cardiac indicators, it can be adjusted to intravenous injection of daratumumab); Bortezomib 1.3 mg/m2 d1, 8, 15, 22; D1, 8, 15, 22; Dexamethasone 20 mg d1, 2, 8, 9, 15, 16, 22, 23. When NTProBNP is greater than 5400ng/ml, bortezomib 1.0mg/m2; When NTProBNP is greater than 8500ng/ml, bortezomib is 0.7mg/m2. When NTProBNP is greater than 10000ng/ml, bortezomib is temporarily not allowed; NTProBNP greater than 4500ng/ml dexamethasone starts at 10 mg/dose. All patients were given Dapagliflozin 10mg/day at the beginning of treatment (creatinine clearance rate greater than 20ml/min).
Study: NCT04584892
Drug: Turoctocog alfa
Normalized name: Turoctocog alfa
DrugBank: Turoctocog alfa (DB09109)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Patients will be treated with commercially available NovoEight® (turoctocog alfa) according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available NovoEight® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Study: NCT03851081
Drug: Vincristine Sulfate Liposome
Normalized name: vincristine sulfate liposome
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05272709
Drug: TT-702
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT-702 will be administered orally, once daily, for up to 12 months.
Study: NCT05272709
Drug: Darolutamide
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darolutamide will be administered orally, twice daily, for up to 12 months.
Study: NCT05282251
Drug: Intrapleural bupivacine nebulization
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrapleural nebulization of bupivacine (10 ml of bupivacaine 0.5%) + Intravenous normal saline as a placebo
Study: NCT04932382
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: will be used 3 h before IUD insertion
Study: NCT04849299
Drug: AT-527 550 mg + cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 mg AT-527 alone on Day 1 and 550 mg AT-527 plus 600 mg cyclosporine administered simultaneously on Day 7 Other Names: AT-527 is also known as R07496998
Study: NCT04849299
Drug: AT-527 550 mg + cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 mg AT-527 alone on Day 1 and 550 mg AT-527 plus 600 mg cyclosporine administered on Day 7 (with dosing offset by 2 hrs) Other Names: AT-527 is also known as R07496998
Study: NCT04737837
Drug: lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lacosamide as first add on therapy
Study: NCT05625347
Drug: single dose (100 mg) of ASA
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: powder for oral inhalation via a Dry Powder Inhaler (DPI)
Study: NCT05204069
Drug: Instillation of cyclopentolate
DrugBank: Cyclopentolate (DB00979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Instillation of cyclopentolate of 3 drops of cyclopentolate at t0',t5' and t10' with to induce a certain level of cycloplegia and evaluate manifest refraction at t45' using the RetinoMax Device.
Study: NCT05073744
Drug: Nalbuphine
Normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalbuphine hydrochloride injection or morphine hydrochloride injection is used for perioperative tumor ablation
Study: NCT05073744
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine hydrochloride injection is used for perioperative tumor ablation
Study: NCT05905887
Drug: Rivoceranib Mesylate, Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).~Rivoceranib 400 mg orally once a day.
Study: NCT05805839
Drug: C-11 ER176 Radiotracer
Normalized name: choline C-11
DrugBank: Choline C-11 (DB09563)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered at a single time IV prior to the PET imaging. The injected dose of C-11 ER176 will be 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi).
Study: NCT05805839
Drug: C11 Pittsburgh Compound B
Normalized name: Choline C11
DrugBank: Pittsburgh Compound B (DB15161)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered at a single time IV prior to the PET imaging. The injected dose of C-11 PiB will be 555 MBq (range 370 - 629 MBq).
Study: NCT05861765
Drug: Papaverine Hydrochloride
Normalized name: Papaverine Hydrochloride
DrugBank: Papaverine (DB01113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Slowly inject 10ml of papaverine hydrochloride solution (30mg/10ml) through the successfully implanted radial artery sheath, and continuously drip papaverine hydrochloride solution (60mg/500ml, 4ml/min) through the artery sheath during the operation. The compatible solutions are normal saline(0.9%);
Study: NCT04825860
Drug: SEP-363856 50 mg
Normalized name: atropine sulfate / benzoic acid / hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate Oral Tablet [Uri-Sep]
DrugBank: SEP-363856 (DB15665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
Study: NCT04825860
Drug: SEP-363856 75 mg
Normalized name: atropine sulfate / benzoic acid / hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate Oral Tablet [Uri-Sep]
DrugBank: SEP-363856 (DB15665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
Study: NCT05394233
Drug: Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed
Normalized name: Tislelizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab: 7.5 mg/kg administered as an intravenous infusion on Day 1 of each 3-week cycle Cisplatin 75 mg/m2 will be administered as an intravenous infusion over 2 hours, every 3 weeks, Pemetrexed, 500 mg/m2, intravenously every 3 weeks, Tislelizumab, 200 mg IV every 3 weeks